These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 16220095)

  • 1. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.
    Mitchell DK; Ruben FL; Gravenstein S
    Pediatr Infect Dis J; 2005 Oct; 24(10):925-7. PubMed ID: 16220095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season].
    Lupulescu E; Ioniţă E; Botez D; Matepciuc M; Tabra ME; Tecu C; Alexandrescu V; Munţiu A
    Bacteriol Virusol Parazitol Epidemiol; 1997; 42(1-2):110-2. PubMed ID: 9235136
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience.
    Neuzil KM; Dupont WD; Wright PF; Edwards KM
    Pediatr Infect Dis J; 2001 Aug; 20(8):733-40. PubMed ID: 11734733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a paediatric presentation of an influenza vaccine.
    Gonzalez M; Pirez MC; Ward E; Dibarboure H; García A; Picolet H
    Arch Dis Child; 2000 Dec; 83(6):488-91. PubMed ID: 11087282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivated influenza virus vaccines in children.
    Ruben FL
    Clin Infect Dis; 2004 Mar; 38(5):678-88. PubMed ID: 14986252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
    J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY; Shao PL; Chang LY; Huang YC; Chiu CH; Hsieh YC; Lin TY; Huang LM
    Vaccine; 2010 Aug; 28(36):5864-70. PubMed ID: 20600484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
    Oh CE; Lee J; Kang JH; Hong YJ; Kim YK; Cheong HJ; Ahn YJ; Kim SH; Lee HJ
    Vaccine; 2010 Aug; 28(36):5857-63. PubMed ID: 20600483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
    Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients.
    Van Hoecke C; Prikazsky V; Utö I; Menschikowski C
    Gerontology; 1996; 42(4):190-8. PubMed ID: 8832266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.
    Lee J; Lee KY; Kim JH; Kim CS; Eun BW; Kim HM; Kim DH; Hong YJ; Choi YY; Jo DS; Ma SH; Kang JH
    J Korean Med Sci; 2018 Mar; 33(13):e100. PubMed ID: 29573247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
    Gresset-Bourgeois V; Leventhal PS; Pepin S; Hollingsworth R; Kazek-Duret MP; De Bruijn I; Samson SI
    Expert Rev Vaccines; 2018 Jan; 17(1):1-11. PubMed ID: 29157068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP; Robertson CA; Talbot HK; Decker MD
    Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors.
    Jackson LA; Austin G; Chen RT; Stout R; DeStefano F; Gorse GJ; Newman FK; Yu O; Weniger BG;
    Vaccine; 2001 Sep; 19(32):4703-9. PubMed ID: 11535320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influenza live attenuated intra-nasal vaccines].
    Weil-Olivier C
    Arch Pediatr; 2010 Jun; 17(6):904-5. PubMed ID: 20654953
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing.
    Bae EY; Choi UY; Kwon HJ; Jeong DC; Rhim JW; Ma SH; Lee KI; Kang JH
    Clin Vaccine Immunol; 2013 Jun; 20(6):811-7. PubMed ID: 23536692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of reactogenicity, safety and immunogenicity of inactivated virosomal split influenza vaccine "Grifor" during phase I clinical trial].
    Zverev VV; Korovkin SA; Mironov AN; Mel'nikov SIa; Mikhaĭlova NA; Kostinov MP; Dyldina NV; Zhirova SN
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (1):26-31. PubMed ID: 19338233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.